Long-term pasireotide therapy in acromegaly: extensive real-life experience of a referral center

Purpose Pasireotide is a novel therapeutic option for patients with acromegaly resistant to first-generation somatostatin receptor ligands. To date, real-life data are still scant, therefore, the aim of the current study is to evaluate the impact of long-term pasireotide therapy on disease control,...

Full description

Saved in:
Bibliographic Details
Published in:Journal of endocrinological investigation 2024-08, Vol.47 (8), p.1887-1901
Main Authors: Pirchio, R., Auriemma, R. S., Vergura, A., Pivonello, R., Colao, A.
Format: Article
Language:English
Subjects:
Acromegaly
Acromegaly - drug therapy
Adult
Aged
Blood Glucose - analysis
Brain tumors
Diabetes
Diabetes mellitus
Disease control
Endocrinology
Female
Follow-Up Studies
Glucagon
Glucagon-like peptide 1
Hemoglobin
High density lipoprotein
Humans
Hyperglycemia
Insulin
Insulin-like growth factor I
Insulin-Like Growth Factor I - analysis
Insulin-Like Growth Factor I - metabolism
Internal Medicine
Male
Medicine
Medicine & Public Health
Metabolic Diseases
Middle Aged
Original
Original Article
Pituitary
Referral and Consultation
Retrospective Studies
Somatostatin
Somatostatin - administration & dosage
Somatostatin - analogs & derivatives
Somatostatin - therapeutic use
Treatment Outcome
Triglycerides
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Pasireotide is a novel therapeutic option for patients with acromegaly resistant to first-generation somatostatin receptor ligands. To date, real-life data are still scant, therefore, the aim of the current study is to evaluate the impact of long-term pasireotide therapy on disease control, pituitary tumor size, gluco-insulinemic and lipid profile in a real-life setting. Methods Retrospective study of data prospectively collected, evaluating hormonal, tumoral, and metabolic data of 28 patients with acromegaly administered with pasireotide in a pituitary tertiary referral center. Results Within the first 12 months of treatment, 70.4% of patients achieved normal IGF-I levels, which was maintained at 36-month evaluation in these responders patients. Patients who started with pasireotide 60 mg monthly exhibited significantly lower IGF-I levels after 36 months ( p  = 0.05) as compared to patients administered first with pasireotide 20 or 40 mg monthly. The maximal tumoral diameter was significantly decreased after 12 months of pasireotide ( p   25% of baseline measurement) after 36 months of treatment. Fasting glucose significantly increased during the first 6 months ( p  
ISSN:1720-8386
0391-4097
1720-8386
DOI:10.1007/s40618-023-02299-7